Literature DB >> 3872165

Tumour inhibitory effects of TCGF/IL-2/-containing preparations.

J Bubeník, M Indrová, P Perlmann, K Berzins, O Mach, J Kraml, A Toulcová.   

Abstract

Supernatants from ConA-stimulated rat spleen cell cultures and from cultures of PMA-stimulated murine lymphoma subline EL-4TF were found to contain TCGF and to inhibit growth of a transplantable, MC-induced sarcoma MC11 in syngeneic mice. Tumour-inhibitory effects of the supernatants were dependent on local and repeated administration. Prior to use of the supernatants obtained from PMA-stimulated EL-4TF cell cultures, the dialysable PMA had to be removed; contamination with PMA was found to abolish the tumour-inhibitory effect of the supernatants and to produce enhancement of tumour growth. A significant tumour-inhibitory effect has also been obtained with partially purified TCGF prepared from culture supernatants of cloned EL-4TF cells by ammonium sulphate precipitation, ion-exchange (FPLC) chromatography, and AcA 44 Ultrogel filtration.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3872165     DOI： 10.1007/bf00199313

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  24 in total

1.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

2.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

3.  Phorbol myristate acetate and in vitro T lymphocyte function. I. PMA may contaminate lymphokine preparations and can interfere with interleukin bioassays.

Authors:  C G Orosz; D C Roopernian; F H Bach
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

4.  Solubilized tumour-associated antigens of methyl-cholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests.

Authors:  J Bubeník; M Indrová; S Nemecková; M Malkovský; B Von Broen; V Pálek; J Anderlíková
Journal:  Int J Cancer       Date:  1978-03-15       Impact factor: 7.396

5.  The reproducibility of fast protein liquid chromatography of pyridoxalated haemoglobin copolymerized with serum albumin.

Authors:  T I Pristoupil; M Kramlová; V Fricová; J Kraml
Journal:  J Chromatogr       Date:  1983-12-02

6.  Properties of sodium dodecyl sulfate-denatured Interleukin 2.

Authors:  B Caplan; C Gibbs; V Paetkau
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity.

Authors:  K Welte; C Y Wang; R Mertelsmann; S Venuta; S P Feldman; M A Moore
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

8.  Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.

Authors:  J Bubeník; P Perlmann; M Indrová; J Símová; T Jandlová; J Neuwirt
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  T-cell growth factor contains activity that supports natural killer activity in vitro.

Authors:  K O Grönvik; J Andersson; G Alm; P Stern
Journal:  Scand J Immunol       Date:  1983-10       Impact factor: 3.487

10.  Purification of murine T cell growth factor. A lymphocyte mitogen with helper activity.

Authors:  A Granelli-Piperno; J D Vassalli; E Reich
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307
View more
  9 in total

Review 1.  Local and regional immunotherapy of cancer with interleukin 2.

Authors:  J Bubeník
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).

Authors:  N Saijo; A Ozaki; H Nakano; M Sakurai; H Takahashi; Y Sasaki; A Hoshi
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases.

Authors:  R Mikysková; J Bubenik; L Mendoza; V Vonka; M Smahel; J Símová; T Jandlová
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Authors:  Jennifer A A Gubbels; Brian Gadbaw; Ilia N Buhtoiarov; Sachi Horibata; Arvinder K Kapur; Dhara Patel; Jacquelyn A Hank; Stephen D Gillies; Paul M Sondel; Manish S Patankar; Joseph Connor
Journal:  Cancer Immunol Immunother       Date:  2011-07-27       Impact factor: 6.968

5.  Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study.

Authors:  V P Rutten; W R Klein; W A De Jong; W Misdorp; W Den Otter; P A Steerenberg; W H De Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo.

Authors:  J Bubeník; M Indrová
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment.

Authors:  J Bubeník; J Símová; D Bubeníková; J Zeuthen; M Indrová
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Local therapy of cancer with free IL-2.

Authors:  Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.